Leukeran

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Gastric CancerAcute Lymphoblastic LeukemiaLeukemiaPancreatic Ductal AdenocarcinomaChronic Lymphocytic LeukemiaHodgkins LymphomaMALT Lymphoma

193 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

1

Leukeran

Akero Therapeutics

Approved

472

Taxol

Teva

Phase 3

443

Opdivo

Bristol-Myers Squibb

Phase 3

244

Keytruda

Merck & Co.

Phase 3

195

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

916

Taxotere

AAvyxa

Phase 3

457

Abraxane

Bristol-Myers Squibb

Phase 3

118

Avastin

Roche

Phase 3

119

Cyramza

Eli Lilly

Phase 3

1010

Elunate

Takeda

Phase 3

7Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia28 trials

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

Terminated·Roche·Phase 4·NCT01283386·26 enrolled

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Completed·Roche·Phase 3·NCT02242942·445 enrolled

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017108

Show 25 more trials

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Completed·Roche·Phase 3·NCT01998880·787 enrolled

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Terminated·Novartis·Phase 3·NCT00748189·447 enrolled

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Completed·GSK·Phase 2·NCT01563055·10 enrolled

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Completed·Roche·Phase 4·NCT01056510·357 enrolled

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Completed·Roche·Phase 3·NCT01905943·979 enrolled

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Completed·Roche·Phase 3·NCT02053610·787 enrolled

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Completed·GSK·Phase 2·NCT01808326·5 enrolled

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Completed·Roche·Phase 2·NCT01868893·20 enrolled

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

Completed·Roche··NCT02915224·50 enrolled

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Terminated·Roche·Phase 1·NCT02336048·38 enrolled

Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Completed·LLeukemia Research Fund·Phase 3·NCT00004218

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Completed·Roche·Phase 3·NCT01010061·787 enrolled

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

Unknown status·SShandong Lanjin Pharmaceuticals Co.,Ltd·Phase 3·NCT01657955·96 enrolled

A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.

Completed·Roche·Phase 2·NCT00532129·100 enrolled

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Terminated·TTG Therapeutics, Inc.·Phase 3·NCT02612311·603 enrolled

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Terminated·Gilead·Phase 3·NCT01980875·57 enrolled

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Completed·Gilead·Phase 1·NCT01088048·241 enrolled

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Completed·PPharmacyclics LLC.·Phase 3·NCT02264574·229 enrolled

Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)

Terminated·CCephalon·Phase 2·NCT00151736·88 enrolled

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Completed·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT01109264·147 enrolled

A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.

Completed·Roche·Phase 2·NCT00738374·97 enrolled

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 3·NCT00262795·206 enrolled

A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting·AstraZeneca·Phase 3·NCT04075292·155 enrolled

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL

Active, not recruiting·AAcerta Pharma BV·Phase 3·NCT02475681·535 enrolled

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors

Active, not recruiting·BBeOne Medicines·Phase 3·NCT06970743·153 enrolled

Lymphoma6 trials

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma

Unknown status·LLymphoma Trials Office·Phase 3·NCT00006250·500 enrolled

Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Unknown status·SScotland and Newcastle Lymphoma Group·Phase 3·NCT00003639·200 enrolled

Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00416377·353 enrolled

Show 3 more trials

Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00417014·358 enrolled

Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025064·260 enrolled

Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach

Unknown status·LLymphoma Trials Office·Phase 3·NCT00003617·200 enrolled

MALT lymphoma2 trials

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 3·NCT00210353·454 enrolled

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Active, not recruiting·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT01808599·112 enrolled

Treatment2 trials

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Unknown status·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 3·NCT04578613·218 enrolled

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Completed·PPharmacyclics LLC.·Phase 3·NCT01722487·269 enrolled

First Line Therapy1 trial

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Completed·Bristol-Myers Squibb·Phase 3·NCT00910910·450 enrolled

8 more indications

Follicular Lymphoma1 trial

Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028691

Chronic Lymphocytic Leukaemia1 trial

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Unknown status·UUniversity of Liverpool·Phase 3·NCT01678430·670 enrolled

Lymphoplasmacytic Lymphoma1 trial

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Completed·—·Phase 3·NCT00608374·400 enrolled

Macroglobulinemia1 trial

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Completed·FFrench Study Group on Chronic Lymphoid Leukemia·Phase 3·NCT00566332·414 enrolled

Hodgkin's Disease1 trial

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease

Completed·MMedical Research Council·Phase 3·NCT00003421·800 enrolled

Mantle Cell Lymphoma1 trial

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT00285389·39 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell1 trial

A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Active, not recruiting·Johnson & Johnson·Phase 3·NCT03462719·211 enrolled

CLL/SLL1 trial

A Global Multicenter Open Label Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib vs Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Recruiting·Ascentage Pharma Group Inc.·Phase 3·NCT06319456·344 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News